Aaron Davidson
Mr. Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life science companies. Mr. Davidson began his career with Lilly, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., Novadaq Technologies, and Tranzyme Pharma. He served on the boards of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalon in 2005 and 2011 respectively and the board of Oncogenex Pharmaceuticals prior to their public listing.
Mr. Davidson earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.
Charlotte Hubbert
Charlotte Hubbert is an Associate at H.I.G. BioVentures focusing on investment opportunities in the life sciences, including therapeutics, diagnostics and medical devices.
Prior to joining H.I.G., Charlotte was an Associate at Accelerator Corporation, an investment vehicle focused on identifying, evaluating, financing and managing emerging therapeutic technologies. During her tenure, Charlotte was involved in the strategic development and management of five companies, including Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori and Pharmselex. Charlotte also currently serves as a member of the Scientific Advisory Board for Oncofactor Corporation.
Charlotte earned a B.S. in Microbiology from the University of Washington and a Ph.D. in Pharmacology and Cancer Biology from Duke University. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the University of Washington. Charlotte is a member of the Kauffman Society of Fellows (Class 14).
Andrew Levin
Andrew focuses on investments in therapeutics and medical devices.
Prior to joining H.I.G., Andrew was the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative, where he led several product development programs and managed strategic research collaborations. Andrew began his investment career at Tang Capital Management where he served as a Principal, supporting public and private investments in the biotech space. He later joined Citadel Investment Group's Global Equities team, as a therapeutics and medtech analyst. Previously, Andrew was a Business Development Manager for Genzyme Cardiovascular and helped successfully shepherd a major clinical in-licensing program.
Andrew earned a BSE in Mechanical Engineering from Princeton University, an MD from Harvard Medical School and a PhD in Bioengineering from M.I.T.
Bruce Robertson
As a Managing Director at H.I.G. BioVentures, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, and Clarus Therapeutics.
Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.
Stephanie Stehman
Stephanie Stehman is an Associate at H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector, including diagnostics, therapeutics, and medical devices.
Prior to joining H.I.G., Stephanie was a Senior Consultant with Scisive Consulting, a strategy consulting firm for healthcare businesses. At Scisive, she worked with a range of medical industry clients to provide strategic, financial, and business development support. This work included numerous opportunity assessments and corporate development projects across multiple therapeutic areas. She has extensive experience working within molecular diagnostics, neurology, and the orphan disease space.
Stephanie earned her B.S. in Biology from Muhlenberg College and her Ph.D. in Cell Biology from Columbia University.
Michael Wasserman
As a Managing Director at H.I.G. BioVentures, Michael Wasserman focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. Michael currently represents H.I.G. on the boards of: HyperBranch Medical Technology, Clarus Therapeutics, CardioFocus and NeuWave Medical.
Prior to joining H.I.G., Michael was with Innovations Foundation, where he focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a Founder of CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.
Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.